Back to top
more

Cerus (CERS)

(Delayed Data from NSDQ)

$1.71 USD

1.71
387,036

+0.01 (0.59%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.71 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CERS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cerus Corporation [CERS]

Reports for Purchase

Showing records 1 - 20 ( 69 total )

Company: Cerus Corporation

Industry: Medical - Products

Record: 1

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CERS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 2

11/02/2017

Daily Note

Pages: 3

SMALL-CAP SQUAWK

Provider: JGR Capital Partners

Price: 10.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 3

10/07/2016

Company Report

Pages: 4

Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 4

12/16/2015

Company Report

Pages: 8

Downgrading from OUTPERFORM to NEUTRAL Following Achievement of Price Target - Maintaining $6.50 PT - Is an ARC Win Already Priced in?

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 5

11/06/2015

Company Report

Pages: 10

3Q15 Recap - Sales Miss - One Step Backward in EU - Two Steps Forward In US with OneBlood - US Rev Ramp Still Anyone''s Guess - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 6

11/02/2015

Daily Note

Pages: 9

Pleasant P-Code Surprise - Helps Open the Market - May Accelerate Contracting - Difficult to Quantify Near Term Impact - Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 7

10/28/2015

Company Report

Pages: 9

3Q15 Preview - Expecting In-line Results - Focus is on ARC - Top Five Account Dialogue - AABB Meeting Activity Seems Good - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 8

08/07/2015

Company Report

Pages: 10

2Q15 Recap - Slightly Better Revenue - EPS Lower - New Positive Signals But US Revenue Still Difficult to Model - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 9

08/03/2015

Company Report

Pages: 8

2Q15 Preview - Expecting In-line Results - Encouraged by July US Win Momentum - We Believe More Wins are Teed Up This Year - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 10

05/06/2015

Company Report

Pages: 9

1Q15 Shows Progress - Sales In-line - EU Unit Growth Solid - US Tone Sounds Good - NIH Contract Announced - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 11

05/01/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 12

05/01/2015

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 13

04/28/2015

Company Report

Pages: 8

1Q15 Preview - Minimal Confidence in 1Q EU Business - Encouraged by the US Post ARC Comments in NEJM Article - Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 14

02/27/2015

Company Report

Pages: 10

4Q14 Sales - 2015 Guide A Little Light Due to Fx - Russia - Volume Guidance Ok

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 15

02/19/2015

Company Report

Pages: 8

4Q14 Preview - Expecting in-Line Financials Driven by Flattish EU Q/Q - Recent US Wins Encouraging - Color on Sales Funnel Will Be Key - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 16

01/08/2015

Company Report

Pages: 9

Update Post Capital Raise - Funded for 2+ Yrs of US Launch - Lowering 2015 Estimates Related to Implementation Nuances - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 17

12/19/2014

Industry Report

Pages: 22

LIFE SCIENCES AND HEALTH CARE-2015 Health Care Sector Outlooks

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 18

12/19/2014

Company Report

Pages: 8

Santa Arrives Early - Brings FDA Approval of Platelet Product 2 Days After Plasma Approval - a Quarter Early - Raising PT from $6.50 to $7.50

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 19

12/19/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences- Upcoming Events for the Week of Dec 22

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 20

12/18/2014

Company Report

Pages: 8

Upping PT to $6.50 on Further De-risking Post Plasma FDA Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party